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ABSTRACT 29 
There is a clear need for new antimicrobials to improve current treatment of chronic 30 
lung infection in people with cystic fibrosis (CF). This study determined the activity of 31 
antimicrobial peptides (AMPs) and ivacaftor, a novel CF transmembrane regulator 32 
potentiator for treatment of CF. Antimicrobial activity of AMPs (LL37, Human β-33 
Defensins [HβD] 1-4 and SLPI) and ivacaftor against clinical respiratory isolates 34 
(Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus spp., 35 
Achromobacter spp. and Stenotrophomonas maltophilia) were determined using radial 36 
diffusion and time-kills assays, respectively. Synergy of LL37 and ivacaftor with 37 
tobramycin was determined by time-kill with in vivo activity of ivacaftor and tobramycin 38 
compared using a murine infection model. LL37 and HβD3 were the most active AMPs 39 
tested with MICs for genera ranging from 1.1-51.9 mg/L and 1-35.4 mg/L, respectively, 40 
with the exception of Achromobacter which was resistant. HβD1 and SLPI 41 
demonstrated no antimicrobial activity. LL37 demonstrated synergy with tobramycin 42 
against 4/5 S. aureus and 2/5 Streptococcus spp. isolates. Ivacaftor demonstrated 43 
bactericidal activity against Streptococcus spp. (mean log10 decrease 3.31 CFU/ml), 44 
bacteriostatic activity against S. aureus (mean log10 change 0.13 CFU/ml) but no 45 
activity against other genera. Moreover, ivacaftor demonstrated synergy with 46 
tobramycin with a mean log10 decrease of 5.72 CFU/ml and 5.53 CFU/ml at 24 hours 47 
for S. aureus and Streptococcus spp., respectively. Ivacaftor demonstrated 48 
immunomodulatory but no antimicrobial activity in a P. aeruginosa in vivo murine 49 
infection model. Following further modulation to enhance activity, AMPs and ivacaftor 50 
offer real potential as therapeutics to augment antibiotic therapy of respiratory infection 51 
in CF.  52 
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1. Introduction 58 
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the cystic fibrosis 59 
transmembrane conductance regulator (CFTR) gene. Respiratory failure caused by 60 
repeated cycles of infection and inflammation is the leading cause of morbidity and 61 
mortality in people with CF and is responsible for 80% of deaths [1]. Although 62 
Pseudomonas aeruginosa is the most frequently isolated CF respiratory pathogen [2], 63 
infection caused by other bacteria including Staphylococcus aureus, Burkholderia 64 
cepacia complex, Stenotrophomonas maltophilia, Achromobacter spp. and 65 
Streptococcus spp. [3,4] also occur. As a result, primarily due to increased use of 66 
antibiotics, bacteria causing respiratory infection are becoming progressively more 67 
resistant to conventional antibiotics with up to 45% of CF patients colonised with 68 
multidrug resistant pathogens [5–7]. Furthermore, when chronic infection is 69 
established, pathogens such as P. aeruginosa grow within polymicrobial biofilms in 70 
the CF lung and exhibit increased resistance to antibiotics [8,9]. Tobramycin is the 71 
most frequently prescribed inhaled antibiotic for CF patients with chronic P. aeruginosa 72 
infection [2], with ciprofloxacin frequently prescribed as an oral antibiotic [10]. 73 
However, in a recent study of CF P. aeruginosa isolates in Northern Europe, 60% were 74 
multidrug resistant with 28% and 56% resistant to tobramycin and ciprofloxacin, 75 
respectively [11].Therefore, there is a clear need for novel antimicrobial agents or 76 
combinations of antimicrobials to treat respiratory infection in CF patients.  77 
Antimicrobial peptides (AMPs) form part of the non-specific innate immune response 78 
and have been shown to have antibacterial activity [12]. Some of the most well 79 
characterised AMPs include the human cathelicidin LL37, Human β-defensins 1-4 80 
(HβD1-4) and secretory leukocyte protease inhibitor (SLPI) which are all produced by 81 
the lung epithelium [13–15]. The antibacterial properties of these peptides have been 82 
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previously demonstrated [16–19], but only LL37 has been specifically tested against 83 
clinical CF respiratory isolates.   84 
Ivacaftor is a first-in-class CFTR potentiator that potentiates defective CFTR at the 85 
apical membrane of lung epithelial cells, thus increasing the probability of successful 86 
chloride transport across the membrane [20]. Treatment results in sweat chloride 87 
correction, decreased exacerbation frequency and an improvement in lung function 88 
and quality of life [21]. Furthermore, Reznikov et al. reported that ivacaftor 89 
demonstrated some antimicrobial activity against laboratory and non-CF clinical 90 
methicillin susceptible and resistant S. aureus (MSSA and MRSA) and Streptococcus 91 
pneumoniae isolates [22] and suggested that this may be due to the presence of a 92 
quinolone ring. 93 
The aim of this study was to determine the antimicrobial activity of a number of AMPs 94 
and ivacaftor against clinical CF respiratory isolates from a range of genera. 95 
Furthermore, we investigated if there was synergy between LL37 or ivacaftor and 96 
tobramycin. Finally, a murine infection model was used to compare the in vivo 97 
antimicrobial and immunomodulatory activity of ivacaftor and tobramycin.  98 
  99 
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2. Materials and Methods 100 
2.1.  Bacterial isolates 101 
Eighteen clinical bacterial isolates [P. aeruginosa, n=4; S. aureus n=4 (MRSA, n=3; 102 
MSSA n=1); Streptococcus spp., n=4; Achromobacter spp., n=3 and S. maltophilia, 103 
n=3] were used for susceptibility testing. The isolates were cultured from sputum 104 
samples or bronchoalveolar lavage fluid collected from CF patients attending CF 105 
clinics in Belfast and the University of North Carolina at Chapel Hill. Samples were 106 
cultured on non-selective agar plates and individual colonies sub-cultured to obtain 107 
pure bacterial culture. Bacterial isolates were identified using 16S rRNA sequencing 108 
as described previously [23]. Bacterial isolates were stored at -80°C. P. aeruginosa 109 
ATCC 27853, S. aureus ATCC 29213 and Streptococcus anginosus NCTC 10713 110 
were included as quality control and reference strains. In biofilm assays, S. 111 
epidermidis ATCC 35984 was used as a strong biofilm former (positive control) and a 112 
laboratory S. capitis isolate was used as a weak biofilm former (negative control). P. 113 
aeruginosa strain PAO1 was used for in vivo experiments.  114 
2.2.  Antimicrobials and reagents 115 
 116 
Etest® strips were purchased from bioMerieux (North Carolina, USA). Ivacaftor was 117 
purchased from Selleckchem (Houston, USA), synthetic LL37 and synthetic HβD1-4 118 
from Innovagen (Lund, Sweden) and recombinant human SLPI from R&D Systems 119 
(Minneapolis, USA); All AMPs were active. Tobramycin was obtained from Hospira 120 
(Warwickshire, UK). Ciprofloxacin (≥98% HPLC grade), monobasic and dibasic 121 
sodium phosphate, agarose (Type 1, low EEO), methanol (≥99.9% HPLC grade), 122 
crystal violet (for biofilm staining), Dulbeco’s phosphate buffered saline (PBS) 123 
(endotoxin tested) and trypan blue were all purchased from Sigma-Aldrich (Gillingham, 124 
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UK). Mueller Hinton agar (MHA), Mueller Hinton broth (MHB), Cetrimide agar, 125 
Anaerobe Basal agar (ABA) and Brain Heart infusion (BHI) broth were all purchased 126 
from Oxoid Ltd (Basingstoke, UK). Sterile, defibrinated horse blood was purchased 127 
from TCS Biosciences (Buckingham, UK). Xylazine (Xylacare 2% w/v) and Ketamine 128 
(Narketan 10, 100g/L) were obtained from Animalcare (York, UK) and Ventoquinol 129 
(Buckinghamshire, UK), respectively. IL-6 and KC enzyme-linked immunosorbent 130 
assay (ELISA) kits were purchased from eBioscience (Hatfield, UK) and R&D Systems 131 
(Minneapolis, USA), respectively. 132 
2.3.  MIC testing 133 
The MICs of antibiotics (Supplementary Table 1) routinely used in the treatment of CF 134 
lung infection were determined by Etest® according to the manufacturer’s instructions. 135 
The MICs of AMPs (LL37, HβD1-4 and SLPI) were determined using a radial diffusion 136 
assay (RDA) as previously described [24]. BHI supplemented agar was used with 137 
Streptococcus spp., S. maltophilia and Achromobacter spp. with MHA used for P. 138 
aeruginosa and S. aureus. Peptides were tested at concentrations of 200, 150, 100 139 
and 50 mg/L.  140 
2.4.  LL37 and tobramycin synergy 141 
A modified time-kill assay was used to determine if there was synergy between LL37 142 
and tobramycin against selected isolates (P. aeruginosa [n=5]; S. aureus [n=5] and 143 
Streptococcus spp. [n=5]). Overnight cultures were washed with 10mM sodium 144 
phosphate and adjusted to approximately 1x105 CFU/ml. In a 96-well plate, the 145 
bacterial suspension was incubated with LL37 (64–1 mg/L) alone or in combination 146 
with tobramycin (0.5 MIC for each isolate) for 3 hours at 37°C under aerobic or 147 
microaerophilic conditions. Killing activity was assessed by enumerating on MHA or 148 
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ABA following serial dilution (10-1 to 10-3) in sterile saline. The MBC of LL37 was 149 
determined as the lowest concentration at which there was no growth on the plate. 150 
Synergy was defined as a ≥2 log10 decrease in total viable count (TVC) compared to 151 
the starting inoculum and as a ≥2 log10 decrease in TVC by the combination compared 152 
to the most active single agent [25]. Results are expressed as mean CFU/ml ±SD. 153 
2.5. Time-kill studies  154 
All time-kill experiments were performed according to CLSI standards [25]. Initial time-155 
kill studies were performed using a range of ivacaftor concentrations (32, 16, 8, 4 and 156 
1mg/L) against selected isolates (P. aeruginosa [n=5]; S. aureus [n=5] and 157 
Streptococcus spp. [n=5]); the highest concentration of ivacaftor tested (32 mg/L) was 158 
that previously used by Reznikov et al. [22]. Ivacaftor was dissolved in DMSO and 159 
time-kills were also performed using DMSO (0.32%) as a reagent control. 160 
Subsequently, time-kill assays were performed with these isolates to compare the 161 
activity of ivacaftor (32 mg/L) with ciprofloxacin (5 mg/L; concentration above MIC for 162 
the majority of isolates), a comparator fluoroquinolone. Time-kill assays were 163 
performed in MHB for P. aeruginosa and S. aureus isolates and BHI broth for 164 
Streptococcus spp.  165 
For synergy studies, ivacaftor was used at a concentration of 32 mg/L in combination 166 
with tobramycin at 0.5 MIC. Tobramycin was chosen for synergy studies as it is the 167 
most frequently prescribed inhaled antibiotic in CF and is also frequently prescribed 168 
for treatment of acute infective exacerbations [2]. A no drug control was used in each 169 
assay.  170 
Bacterial cultures and antibiotics were incubated at 37°C under aerobic or 171 
microaerophilic (5% CO2 for Streptococci) conditions. Killing activity was assessed at 172 
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0, 2, 4, 6 and 24 h by carrying out serial dilutions in sterile saline (10-1 to 10-6) followed 173 
by enumerating on MHA or ABA agar. Bactericidal activity was defined as a ≥3 log10 174 
reduction in colony forming units (CFU/ml) in the original inoculum [25]. Synergy was 175 
defined as described above [25] with results for time-kill assays expressed as mean 176 
CFU/ml ±SD. 177 
2.6.  Biofilm Studies 178 
The effect of ivacaftor on bacterial adherence and biofilm formation by all isolates 179 
(clinical isolates n=18; reference strains, n=3) was determined using a previously 180 
described method that quantifies the adherence of bacteria to microtitre plates 181 
(ThermoFisher Scientific, Waltham, USA) [26]. An overnight culture of bacteria was 182 
adjusted to 1x106 CFU/ml with 200 µl added to each well. Ivacaftor (32 mg/L), 183 
ciprofloxacin (5 mg/L) or DMSO (0.32%) were added to the wells and the plates were 184 
incubated for 24 hours at 37°C. The contents of the wells were aspirated, washed 185 
three times with 200 µl sterile PBS and adherent bacteria stained using crystal violet. 186 
Bacterial adherence was quantified by measurement of OD570 (FLUOstar Omega 187 
microplate reader) and compared with an untreated control. Limits for non, weak, 188 
moderate and strong biofilm formation were defined as previously described [26]. 189 
2.7.  In vivo activity using a mouse model of intraperitoneal infection 190 
The in vivo activity of ivacaftor was determined using a systemic sepsis model of 191 
infection in mice. Age and sex matched B6 mice (B6N-Tyrc-Brd/BrdCrCrl [Charles River]) 192 
mice (n=5 per group; 4 male, 1 female) were inoculated intraperitoneally (IP) with 100 193 
µl of P. aeruginosa (PAO1) (6x108 CFU/ml). PAO1 was used as our group and others 194 
have shown that it reproducibly produces intraperitoneal infection in mice [27]. 195 
Ivacaftor (60 µg/mouse), negative control (endotoxin free PBS) or tobramycin (140 196 
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µg/mouse), were administered IP immediately following infection. The dose of 197 
ivacaftor used in this model was calculated based on a single adult dose (150mg) 198 
adjusted for mouse weight (20 g) and the assumption that an adult with CF weighs 50 199 
kg. The dose of tobramycin used was calculated based on the intravenous once daily 200 
dose paediatric regimen of 7 mg/kg adjusted for mouse weight (20 g). The bacterial 201 
load inoculated was chosen to ensure systemic infection was achieved with mice 202 
sacrificed after 4 hours to prevent significant deterioration in health. A peritoneal 203 
lavage was performed with 5 ml of ice-cold sterile PBS, with collected samples stored 204 
on ice. Total viable count of PAO1 from the lavage was determined by enumerating 205 
on cetrimide agar, a P. aeruginosa selective agar. Total cell count and cell viability 206 
were determined following staining with trypan blue using the Countess™ Automated 207 
Cell Counter (Invitrogen). The lavage fluid was centrifuged at 600 xg and the 208 
supernatant used to determine IL-6 and KC (chemokine CXCL1, a functional 209 
homologue of human IL-8) levels by ELISA. Housing and experimentation was carried 210 
out in accordance with the Animal (Scientific Procedures) Act 1986 and current 211 
guidelines approved by the Queen’s University Ethical Review Committee.  212 
2.8.  Statistical analysis 213 
One-way ANOVA and Bonferroni’s Multiple Comparison Tests were used to determine 214 
statistical significance in the biofilm assays and in the in vivo experiments. All analysis 215 
was performed using GraphPad software with a P-value of <0.05 considered 216 
statistically significant. 217 
  218 
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3. Results  219 
3.1.  MIC testing 220 
The MICs of antibiotics routinely used in the treatment of CF lung infection were 221 
determined for all isolates (Supplementary Table 1) with differences in susceptibility 222 
apparent both within and between genera. The majority of P. aeruginosa (4/5; 80%) 223 
and S. aureus (4/5; 80%) isolates were susceptible to tobramycin; however, high 224 
tobramycin MICs were demonstrated for Streptococcus (3/5; 60%), Achromobacter 225 
(3/3; 100%) and S. maltophilia (4/5; 80%) isolates. With the exception of Streptococci, 226 
where all isolates displayed intermediate resistance, based on the breakpoint for S. 227 
pneumoniae, resistance and susceptibility to ciprofloxacin was apparent within each 228 
genera. 229 
The MIC for each antimicrobial peptide against clinical isolates from each genus is 230 
summarised in Table 1 with the MICs of type strains presented for comparison. The 231 
MICs for individual isolates are also presented in Supplementary Table 2. Overall, 232 
LL37 and HβD3 were the most active peptides tested with MICs for genera ranging 233 
from 1.1-51.9 mg/L and 1-35.4 mg/L, respectively, with the exception of 234 
Achromobacter which was resistant. In contrast, HβD1 and SLPI demonstrated no 235 
activity against any isolates at the concentrations tested. Peptide MICs for type strains 236 
were within the range of those for clinical isolates, with the exception of S. anginosus 237 
(NCTC 10713) which was resistant to both HβD2 and HβD4.  238 
3.2. Synergy between LL37 and tobramycin 239 
When combined with tobramycin, LL37 demonstrated no synergistic activity against 240 
P. aeruginosa (Table 2).  In contrast, LL37 demonstrated synergistic activity in 241 
combination with tobramycin against 4/5 S. aureus and 2/5 Streptococcus spp. 242 
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isolates (Table 2). Change in CFU/ml for individual isolates is presented in 243 
supplementary Table 3.  244 
3.3. Bactericidal activity of ivacaftor  245 
When tested alone, ivacaftor demonstrated no antimicrobial activity against P. 246 
aeruginosa at any concentration tested (Fig. 1A). In contrast, at the highest 247 
concentration tested, 32 mg/L, bacteriostatic activity was apparent against all S. 248 
aureus isolates tested (Fig. 1B). Similarly, bacteriostatic (n=3 isolates) and bactericidal 249 
(n=2 isolates) activity was apparent against Streptococcus spp. isolates (Fig. 1C) at 250 
this concentration with no effect apparent against any genera at lower concentrations. 251 
DMSO (0.32%) had no effect on bacterial growth in any assay. Individual time-kill 252 
curves are presented for P. aeruginosa (Supplementary Fig. 1), S. aureus 253 
(Supplementary Fig. 2) and Streptococcus spp. isolates (Supplementary Fig. 3.).  254 
The change in CFU/mL in the presence of ivacaftor, ciprofloxacin or untreated control 255 
at 24 hours for isolates within each genus is summarised in Table 3. Ciprofloxacin 256 
demonstrated bactericidal activity against 16/21 isolates tested with no growth 257 
detected at 24 hours. In contrast, ivacaftor only demonstrated bactericidal activity 258 
against 2/21 isolates tested, both of which were clinical Streptococcus spp. 259 
There was no synergy between ivacaftor and tobramycin against P. aeruginosa (Fig. 260 
2A, Table 4). In contrast, synergy was apparent for 4/5 S. aureus and 4/5 261 
Streptococcus spp. isolates (Fig. 2B & 2C, Table 4). Tobramycin (0.5 MIC) had no 262 
effect on growth of the isolates.   263 
 264 
 265 
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3.4. Effect of ivacaftor on biofilm formation 266 
Biofilm formation was classified as non-adherent, weak, moderate or strong; 2/5 P. 267 
aeruginosa, 1/5 Streptococcus and 1/3 Achromobacter species were non-adherent 268 
and were excluded from further analysis. Of the remaining 17 isolates, 10, 269 
demonstrated weak adherence, 4 demonstrated moderate adherence and 3 were 270 
strong biofilm formers. Treatment with ivacaftor resulted in a significant decrease (P 271 
<0.001) in biofilm formation for 1/3 P. aeruginosa and 2/4 Streptococcus spp. biofilm 272 
forming isolates. However, ivacaftor had no effect on biofilm formation by the 273 
remaining isolates tested (n=14; Fig. 3). Similarly, ciprofloxacin did not decrease 274 
biofilm formation by S. aureus isolates (n=5). However, ciprofloxacin caused a 275 
significant decrease (P <0.001) in biofilm formation for 7/12 isolates (P. aeruginosa, 276 
n=2/3, Streptococcus spp., n=1/4, Achromobacter spp., n=1/2; Stenotrophomonas 277 
spp., n=3/3) across the other genera tested (Fig. 3). DMSO (0.32%) had no effect on 278 
bacterial adherence in any assay. 279 
3.5. In vivo activity of ivacaftor 280 
There was no significant difference between the control group (PBS) and any of the 281 
treatment groups in the total number of cells recovered from the IP lavage or cell 282 
viability (Fig. 4A & 4B). However, compared with control, treatment with tobramycin 283 
caused a significant decrease in the TVC of P. aeruginosa recovered from the 284 
peritoneal lavage (Fig. 4C).  In contrast, there was no significant difference when the 285 
mice were treated with ivacaftor. Both treatments caused a significant reduction in IL-286 
6 levels (Fig. 4D); however, KC was only significantly reduced in the group treated 287 
with tobramycin (Fig. 4E).  288 
  289 
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4. Discussion 290 
As bacteria causing pulmonary infection in CF become progressively more resistant 291 
to conventional antibiotics, interest in the use of AMPs as antimicrobials for treatment 292 
has increased considerably. In the present study, we have shown that LL37 and HβD3 293 
possess antibacterial properties against CF respiratory pathogens such as P. 294 
aeruginosa, MRSA and S. maltophilia. Moreover, both of these AMPs demonstrated 295 
antibacterial activity against clinical isolates which were resistant to antibiotics 296 
routinely used in the treatment of CF pulmonary infection such as ciprofloxacin, 297 
tobramycin and meropenem. SLPI had no activity against any genera tested in the 298 
present study. These results contrast to those previously published which reported 299 
activity of SLPI against both P. aeruginosa and S. aureus [16]. However,  in the study 300 
by Wiedow et al. [16], antibacterial activity of SLPI was assessed using a time-kill 301 
assay with a single dermatological P. aeruginosa and S. aureus isolate. No data were 302 
provided with respect to the antibiotic susceptibility of these two isolates. It is likely 303 
that the isolates used in the present study demonstrated greater inherent antimicrobial 304 
resistance due to prolonged and repeated exposure to antibiotics, which may account 305 
for the lack of concordance between studies. 306 
If used clinically, it is likely that AMPs would need to be administered by inhalation in 307 
combination with an antibiotic to directly target the site of infection. Therefore, we 308 
determined the activity of the most potent AMP, LL37, in combination with tobramycin, 309 
the most frequently prescribed inhaled antibiotic for treatment of P. aeruginosa 310 
pulmonary infection in CF [2].  This combination demonstrated greater antimicrobial 311 
activity than either agent alone against both clinical S. aureus and Streptococcus spp. 312 
isolates. However, no synergistic activity was apparent against P. aeruginosa. In 313 
16 
 
contrast to our findings, it has been previously reported that LL37 and tobramycin in 314 
combination demonstrate enhanced killing of P. aeruginosa biofilms [28]. However, 315 
the concentration of both LL37 (640 mg/L) and tobramycin (160-2560 mg/L) used in 316 
this biofilm killing study were considerably higher than those used in the present study 317 
which ranged from 1-64 mg/L and 0.25-3 mg/L for LL37 and tobramycin, respectively. 318 
Synergy may also have been apparent in our study if we had used both LL37 and 319 
tobramycin at higher concentrations. Despite the excellent antimicrobial activity 320 
demonstrated by LL37 and HβD-3, we were unable to perform further work such as 321 
biofilm assays due to the high cost of these AMPs. 322 
As previous studies have reported that ivacaftor, a first-in-class CFTR potentiator, has 323 
some antimicrobial activity against non-CF clinical isolates such as S. aureus, we 324 
determined its antimicrobial activity against clinical CF respiratory isolates from a 325 
range of genera. Using quantitative culture time-kill assays, we demonstrated activity, 326 
at a concentration of 32 mg/L, against MSSA, MRSA, and Streptococcus spp. isolates 327 
but no activity against P. aeruginosa, S. maltophilia and Achromobacter species. This 328 
result is consistent with the findings of Reznikov et al. who reported that ivacaftor had 329 
some antimicrobial activity against Streptococcus spp. and S. aureus, but was not 330 
active against P. aeruginosa [22]. Similar to Reznikov et al., who reported enhanced 331 
antimicrobial activity when ivacaftor was used in combination with vancomycin or 332 
ciprofloxacin, we also found a synergistic effect against S. aureus and Streptococcus 333 
spp. when ivacaftor was combined with tobramycin.  334 
Reznikov et al. suggested that the antimicrobial activity of ivacaftor may be due to the 335 
presence of a quinolone ring in its structure, similar to that of fluoroquinolone 336 
antibiotics such as ciprofloxacin [22]. Quinolones are broad spectrum antibiotics and 337 
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are typically more active against Gram negative bacteria. In the present study, 338 
ciprofloxacin demonstrated bactericidal activity against both Gram-positive bacteria 339 
(S. aureus and Streptococcus spp.) and Gram-negative bacteria (P. aeruginosa, S. 340 
maltophilia and Achromobacter spp.), consistent with broad-spectrum activity 341 
expected from a conventional quinolone antibiotic.  In contrast, ivacaftor had no activity 342 
against any of the Gram negative isolates tested, suggesting that its antimicrobial 343 
effect may not be directly related to the quinolone ring in the structure. Alternatively, 344 
lack of activity against Gram negative bacteria could be due to a number of other 345 
potential mechanisms such as inability to cross the outer membrane and enzymatic 346 
inactivation.    347 
In addition to clinical outcomes, the effect of ivacaftor treatment on the CF lung 348 
microbiota was also determined in the GOAL study, a longitudinal cohort study of 151 349 
CF patients before and up to 6 months after ivacaftor initiation. A significant reduction 350 
in the number of patients from whom P. aeruginosa was cultured from sputum samples 351 
either through a decrease in P. aeruginosa culture positivity over 6 months [29] or 352 
change from P. aeruginosa culture positive to negative over the course of a year [30] 353 
was reported. In contrast, there was no significant change in sputum culture positivity 354 
for MRSA, MSSA, Stenotrophomonas spp. or Achromobacter spp. [29,30]. Similarly, 355 
in a small study of three paediatric CF patients, a reduction in the relative abundance 356 
of Streptococcus spp. was reported following treatment with ivacaftor. The results of  357 
our study suggest that these changes in Streptococcus relative abundance could be 358 
due to the antimicrobial activity of ivacaftor on this genus; however, the increased 359 
abundance of other genera detected could also account for this change [31].  In 360 
contrast, our results, which clearly show that ivacaftor has no direct antimicrobial 361 
activity against P. aeruginosa, growing planktonically or in biofilm, suggest that the 362 
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change in P. aeruginosa culture positivity reported in the GOAL study is more likely 363 
attributed to increased mucociliary clearance resulting in increased clearance of 364 
biofilm from the airways. The concentration of ivacaftor achieved in sputum following 365 
oral administration has not been reported to date; however, it is likely to be significantly 366 
lower than the reported serum levels of ~1.4 mg/L [32]. Therefore, the concentration 367 
of ivacaftor (32 mg/L) which demonstrated antimicrobial activity in both our study and 368 
that of Reznikov et al. [22] is likely to be considerably higher than that achievable in 369 
sputum following oral administration. This further supports the hypothesis that 370 
changes in pathogen culture positivity reported post-ivacaftor treatment are not as a 371 
result of a direct antimicrobial effect.  372 
Given that pulmonary infection in the CF airways involves bacterial growth in biofilms 373 
[8,9], we also determined the effect of ivacaftor on biofilm formation. The effect of 374 
ciprofloxacin on biofilm formation was also determined to enable comparison between 375 
ivacaftor and a fluoroquinolone antibiotic with a related chemical structure. In general, 376 
ivacaftor had limited effect on biofilm formation. However, as the majority of isolates 377 
demonstrated weak adherence, any change attributable to the use of ivacaftor was 378 
difficult to detect. The decrease in adherence for 2/5 Streptococcus spp. isolates is 379 
likely due to the bactericidal activity of ivacaftor against these isolates. In contrast, 380 
ivacaftor had no antimicrobial activity against P. aeruginosa and thus the decrease in 381 
biofilm formation with one P. aeruginosa isolate is indicative of inhibition of adherence. 382 
Ciprofloxacin demonstrated bactericidal activity against the majority of isolates tested; 383 
therefore, inhibition of biofilm formation could be as a result of either a direct effect on 384 
bacterial adherence or bacterial cell death before adherence could occur.  385 
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It has been previously reported that ivacaftor has some immunomodulatory activity 386 
with Bratcher et al. (2015) demonstrating a decrease towards normalisation of blood 387 
leukocyte activation following ivacaftor treatment [33]. To establish whether ivacaftor 388 
exhibited any antimicrobial or immunomodulatory activity in vivo, an acute systemic 389 
mouse infection model was used; mice were administered ivacaftor or tobramycin at 390 
doses approximately reflecting those used in humans. Ivacaftor demonstrated no 391 
antimicrobial activity in this model; however, there was some indication of modulation 392 
of the innate immune response, based on the reduced production of cytokines and 393 
chemokines. The immunomodulatory effect of fluoroquinolones has been widely 394 
documented [34]; furthermore, in a mouse injury model, treatment with ciprofloxacin 395 
decreased production of IL-6 and KC [35]. A subset of fluoroquinolones with the 396 
cyclopropyl moiety have been linked to this immunomodulatory activity, although the 397 
mechanism has yet to be elucidated [34]. The similarity in structure between ivacaftor 398 
and fluoroquinolones could potentially explain the immunomodulatory activity 399 
demonstrated here.  400 
There are a number of limitations to this study. Firstly, the AMPs used were expensive 401 
restricting the volumes that could be used for testing; therefore, we could not 402 
determine MIC by the preferred microbroth dilution method or bactericidal activity 403 
using time-kill assays. This also limited the number and range of isolates which could 404 
be tested. Physiological conditions may also be important when evaluating AMPs as 405 
potential novel antimicrobial therapies. It has been suggested that higher salt 406 
concentration in CF airway surface liquid could reduce the antimicrobial activity of 407 
AMPs [36] by affecting the ionic interaction between the AMPs and bacterial 408 
membranes. Moreover, It has also been demonstrated that in CF sputum, LL37 is 409 
inactivated by binding to DNA, F-actin and cell debris bundles [37]. In contrast, it has 410 
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also been demonstrated that the presence of carbonate, which is found in many 411 
microenvironments of the body including the respiratory tract, can greatly enhance 412 
bacterial susceptibility to AMPs under physiological ionic conditions [38]. Therefore, 413 
further work testing AMP activity under conditions more reflective of the environment 414 
present in the CF airways would be required if these compounds were being 415 
considered as potential therapeutics to treat CF pulmonary infection. Furthermore, 416 
tobramycin was the only antibiotic used in synergy studies with LL37 and ivacaftor. 417 
Given the wide range of antibiotics used in the prophylaxis and treatment of CF 418 
pulmonary infection, future work to determine synergy between an extended range of 419 
antibiotics and LL37/ivacaftor could be of potential clinical benefit. 420 
 421 
  422 
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5. Conclusion 423 
In summary, we have shown that the AMPs, LL37 and HβD3, demonstrate 424 
antimicrobial activity against CF pathogens from a range of genera with LL37 also 425 
demonstrating synergistic activity, in combination with tobramycin, against S. aureus 426 
and Streptococcus spp. isolates. Similarly, ivacaftor demonstrated bactericidal activity 427 
against S. aureus and Streptococcus spp. isolates but no activity against Gram-428 
negative bacteria. There is a low propensity for the development of resistance to AMPs 429 
due to the interaction of the peptides with the cytoplasmic membrane of bacteria and 430 
their bactericidal nature [12]. Therefore, AMPs could potentially be developed as novel 431 
therapeutic options but further work is required to enhance their activity.  432 
 433 
 434 
 435 
  436 
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Table 1 
Antimicrobial activity (MIC range) of antimicrobial peptides against CF respiratory isolates and reference strains P. aeruginosa 
(ATCC 27853), S. aureus (ATCC 29213) and S. anginosus (NCTC 10713).  
   
 MIC Range (mg/L) 
Genus LL37 HβD1 HβD2 HβD3 HβD4 SLPI 
Pseudomonas (n=4) 3.9-22.8 >200 43.4->200 6.4-17.6 39.1-49.3 >200 
ATCC 27853 3.2 >200 28.6 13.9 17.8 >200 
Staphylococcus (n=4) 15.7-29.9 >200 >200 8.9-9.6 >200 >200 
ATCC 29213 21.5 >200 >200 12.7 >200 >200 
Streptococcus (n=4) 2.4-33.2 >200 3.8-49.9 4.8-18.9 32.4-45.7 >200 
NCTC 10713 28.5 >200 >200 18.6 >200 >200 
Achromobacter (n=3) 36.6->200* >200 >200 50.6->200* >200 >200 
S. maltophilia (n=3) 3.3-34.6 >200 47.7->200* 9.6-29.4 51.5->200* >200 
 
*only active against 1 isolate 
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Table 2.  
Mean log change in CFU/ml (±SD) at 3 hours to determine synergistic activity between LL37 and tobramycin.  
 
 Log change in CFU/ml (mean ± SD) 
Genus LL37 
(0.5 MIC) 
Tobramycin  
(0.5 MIC) 
LL37 (0.5 MIC) + 
tobramycin (0.5 
MIC) 
Control 
Pseudomonas 
(n=5) 
-0.31 (±0.22) -0.58 (±0.31) -0.92 (±0.37) 0.02 (±0.02) 
Staphylococcus 
(n=5) 
-1.37 (±0.26) -0.04 (±0.07) -3.82 (±1.05) 0.01 (±0.01) 
Streptococcus 
(n=5) 
-0.13 (±0.15) -1.12 (±1.51) -2.53 (±1.96) 0.03 (±0.03) 
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Table 3 
Mean log change in CFU/mL (± SD) at 24 hours following challenge with ivacaftor or ciprofloxacin. 
 
 Log change in CFU/mL (mean ± SD) 
Genus Ivacaftor  
(32 mg/L) 
Ciprofloxacin  
(5 mg/L) 
Control 
Pseudomonas (n=5) 4.44 (±0.30) -5.83 (±0.28) 3.84 (±0.79) 
Staphylococcus (n=5) -0.51 (±0.61) -2.06 (±4.33) 3.37 (±0.44) 
Streptococcus (n=5) -3.16 (±2.25) -4.50 (±1.35) 3.63 (±0.51) 
Achromobacter (n=3) 2.83 (±0.27) -1.63 (±3.84) 3.01 (±0.17) 
Stenotrophomonas (n=3) 2.69 (±0.16) -5.83 (±0.29) 3.11 (±0.01) 
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Table 4 
Mean log change in CFU/ml (± SD) at 24 hours to determine synergistic activity between ivacaftor and tobramycin. 
 
 Log change in CFU/mL (mean ± SD) 
Genus Ivacaftor 
(32 mg/L) 
Tobramycin  
(0.5 MIC) 
Ivacaftor (32 mg/L) & 
Tobramycin (0.5 MIC) 
Control 
Pseudomonas (n=5) 3.91 (±1.57) 3.69 (±0.66) 2.46 (±1.61) 3.84 (±0.49) 
Staphylococcus (n=5) 0.13 (±0.45) 3.53 (±0.15) -5.72 (±0.17) 3.51 (±0.27) 
Streptococcus (n=5) -3.31 (±2.13) 2.38 (±1.42) -5.53 (±0.61) 3.49 (±0.59) 
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Fig. 1. Time-kill curves for A) P. aeruginosa (n=5), B) S. aureus (n=5) and C) 
Streptococcus spp. (n=5) challenged with ivacaftor at a range of concentrations (1-32 
mg/L) plotted as the mean change in CFU/ml (±SD).  
Fig. 2. Activity of ivacaftor and tobramycin (0.5 MIC) in combination against A) P. 
aeruginosa (n=5), B) S. aureus (n=5) and C) Streptococcus spp. (n=5); the mean 
change in CFU/ml (±SD) for each genera is shown.  
Fig. 3. Effect of ivacaftor (32mg/L) and ciprofloxacin (5mg/L) on biofilm formation by 
P. aeruginosa (n=3), S. aureus (n=5), Streptococcus spp. (n=4), Achromobacter spp. 
(n=2) and Stenotrophomonas spp. (n=3). Adherence is plotted as the mean of 8 
replicates (±SD). Non-adherent bacteria were not included in the analysis. P≤0.01**, 
P≤0.001***.  
Fig. 4. Effect of ivacaftor in comparison to tobramycin on intraperitoneal infection using 
P. aeruginosa (PAO1) in C57bl6 albino mice. A) total number of cells recovered from 
the peritoneal lavage, B) cell viability, C) Total viable count (TVC) of P. aeruginosa 
recovered from the peritoneal lavage, D) IL-6; E) KC. Results are plotted as the mean 
value from 5 mice (±SD). P≤0.05*, P≤0.01**, P≤0.001***. 
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Fig. 3. 
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Supplementary Table 1. MIC (mg/L) of a panel of antibiotics against the isolates tested. Breakpoints, where available, are taken from the EUCAST guidelines [39]. 
   Amoxicillin  Azithromycin  Ceftazidime  Chloramph 
enicol 
Ciprofloxacin  Clindamycin  Co‐ 
amoxiclav 
Colistin  Doxycycline  Meropenem  Tobramycin 
P. aeruginosa                                  
B004 V2S2B  >256  >256  >256  12  2  >256  48  3  24  12  6 
B008 V1S1C  3  48  1.5  16  3  >256  3  1  >256  0.094  1.5 
C041 V1S1A  >256  48  1  >256  0.125  >256  >256  1.5  >256  0.38  0.75 
C070 V1S1A  >256  128  1  >256  0.5  >256  256  1  >256  0.094  1 
ATCC 27853  >128  32  1  >256  0.25  >256  128  4  48  0.25  0.5 
Breakpoints        R>8     S≤0.5, R>1        R>4     S≤2, R>8  R>4 
S. aureus                                  
BO38 V1S1A#  24  >256  64  3  0.38  0.047  12  >256  4  0.5  32 
BO87 V1S1A  1.5  >256  16  3  0.19  0.25  8  >256  0.094  0.38  0.38 
BO42 V2E1A#  24  >256  >256  2  >32  8  48  96  0.094  >32  0.75 
BOO8 V2E1B#  8  >256  256  2  >32  0.047  12  32  0.064  1  0.094 
ATCC 29213  0.5  0.12  8  2  0.5  0.06  0.25  >256  0.19  0.06  0.5 
Breakpoints     S≤1, R>2     R>8  R>1  S≤0.25, 
R>0.5 
      S≤1, R>2     R>1 
Streptococcus sp.                                  
B012 V1S1Q (S. anginosus)  0.064  0.38  3  2  1.5  0.094  0.094  >256  3  0.064  96 
B024 V1S1D (S. mitis)  0.032  6  1  1.5  4  0.094  0.047  >256  1.5  0.064  96 
B003 V1S1T (S. constellatus)  0.5  >256  4  2  1  0.125  0.25  64  12  0.094  0.125 
C063 V1S1B (S. constellatus)  0.094  0.19  2  1.5  1.5  0.094  0.094  >256  1.5  0.094  3 
NCTC 10713 (S. anginosus)  0.19  0.25  3  2  1  0.064  0.38  >256  1  0.064  192 
Breakpoints  S≤0.5, R>2  S≤0.25, 
R>0.5* 
   R>8*  S≤0.25, 
R>0.5* 
R>0.5        S≤1, R>2*  R>2    
Achromobacter sp.                                  
BO64 V2S2K (A. insolitus)  4  32  2  2  1.5  >256  8  0.38  1.5  0.38  12 
B125 V1S1A (A. insolitus)  >256  >256  >256  3  >32  >256  >256  0.25  198  >32  >1024 
BO32 V2E1D (A. spanius)    >256  16  6  >32  >256  3  >256  16    >1024 
Breakpoints  No breakpoints available       
S. maltophilia                                 
BO46 V1S1E  4  >256  0.75  2  4  >256  1.5  32  1.5  2  1.5 
BO74 V2S2E  >256  32  32  3  2  >256  >256  4  3  >32  48 
BO41 V1S1K    >256  96  8  >32  >256  64  0.38  48  >32  96 
Breakpoints  No breakpoints available       
#MRSA; *Indicates breakpoints for S. pneumoniae as no breakpoints available for S. viridans group
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Supplementary Table 2. MIC (mg/L) of antimicrobial peptides against CF respiratory isolates 
 
Isolate LL37 HβD1 HβD2 HβD3 HβD4 SLPI 
P. aeruginosa       
B004 V2S2B 22.8 ≥200 ≥200 8.1 49.3 ≥200 
B008 V1S1C 3.9 ≥200 43.4 6.4 46.6 ≥200 
C041 V1S1A 9.5 ≥200 51.3 9.6 44.1 ≥200 
C070 V1S1A 9.7 ≥200 47.7 17.6 39.1 ≥200 
ATCC 27853 3.2 ≥200 28.6 13.9 17.8 ≥200 
S. aureus       
BO38 V1S1A 29.9 ≥200 ≥200 9.2 ≥200 ≥200 
BO87 V1S1A 17.8 ≥200 ≥200 8.9 ≥200 ≥200 
BO42 V2E1A 22.4 ≥200 ≥200 9.4 ≥200 ≥200 
BOO8 V2E1B 15.7 ≥200 ≥200 9.6 ≥200 ≥200 
ATCC 29213 21.5 ≥200 ≥200 12.7 ≥200 ≥200 
Streptococcus spp.       
B012 V1S1Q (S. anginosus) 2.4 ≥200 49.9 8.9 45.7 ≥200 
B024 V1S1D (S. mitis) 33.2 ≥200 42.9 13.9 32.4 ≥200 
B003 V1S1T (S. constellatus) 6.5 ≥200 3.8 4.8 38.5 ≥200 
C063 V1S1B (S. constellatus) 29.0 ≥200 43.0 18.9 36.0 ≥200 
NCTC 10713 (S. anginosus) 28.5 ≥200 ≥200 18.6 ≥200 ≥200 
Achromobacter sp.       
BO64 V2S2K (A. insolitus) 36.6 ≥200 ≥200 50.6 ≥200 ≥200 
B125 V1S1A (A. insolitus) ≥200 ≥200 ≥200 ≥200 ≥200 ≥200 
BO32 V2E1D (A. spanius) ≥200 ≥200 ≥200 ≥200 ≥200 ≥200 
S. maltophilia       
BO46 V1S1E 3.3 ≥200 ≥200 23.6 ≥200 ≥200 
BO74 V2S2E 34.6 ≥200 ≥200 29.4 ≥200 ≥200 
BO41 V1S1K 18.6 ≥200 47.7 9.6 51.5 ≥200 
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Supplementary Table 3. Synergy between LL37 and tobramycin against CF respiratory isolates (change in log CFU/ml) at 3 hours. 
 
 Log change in CFU/ml (±SD) 
 Control LL37 (0.5 MIC) + 
tobramycin (0.5 MIC) 
LL37  
(0.5 MIC) 
Tobramycin 
(0.5 MIC) 
P. aeruginosa     
B004 V2S2B 0.02 -1.17 -0.17 -0.90 
B008 V1S1C 0.00 -0.70 -0.55 -0.46 
C041 V1S1A 0.01 -1.52 0.05 -0.96 
C070 V1S1A 0.07 -0.58 -0.41 -0.40 
ATCC 27853 0.01 -0.62 -0.48 -0.16 
Mean 0.02 (±0.02) -0.92 (±0.37) -0.31 (±0.22) -0.58 (±0.31) 
S. aureus     
BO38 V1S1A 0.01 -1.72 -0.91 -0.15 
BO87 V1S1A 0.02 -4.30* -1.61 0.02 
BO42 V2E1A 0.02 -4.48* -1.64 0.03 
BOO8 V2E1B 0.01 -4.30* -1.40 0.00 
ATCC 29213 0.00 -4.30* -1.30 -0.08 
Mean 0.01 (±0.01) -3.82 (±1.05) -1.37 (±0.26) -0.04 (±0.07) 
Streptococcus spp.     
B012 V1S1Q (S. anginosus) 0.01 -4.18* -0.10 -0.17 
B024 V1S1D (S. mitis) 0.02 -4.05* -0.26 -4.05 
B003 V1S1T (S. constellatus) 0.08 0.21 0.14 0.03 
C063 V1S1B (S. constellatus) 0.01 -0.49 -0.18 -0.38 
NCTC 10713 (S. anginosus) 0.01 -4.14* -0.24 -1.01 
Mean 0.03 (±0.03) -2.53 (±1.96) -0.13 (±0.15) -1.12 (±1.51) 
 
*Synergy (defined as a ≥2 log10 decrease in total viable count (TVC) compared to the starting inoculum and as a ≥2 log10 decrease in 
TVC by the combination compared to the most active single agent) 
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Supplementary Figure 1. Antimicrobial activity of ivacaftor at a range of concentrations 
against P. aeruginosa isolates; A) B004 V2S2B, B) B008 V1S1C, C) C041 V1S1A, D) 
C070 V1S1A and E) ATCC 27853. 
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Supplementary Figure 2. Antimicrobial activity of ivacaftor at a range of 
concentrations against S. aureus isolates; A) B038 V1S1A, B) B042 V2E1A, C) B087 
V1S1A, D) B008 V2E1B and E) ATCC 29213. 
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Supplementary Figure 3. Antimicrobial activity of ivacaftor at a range of concentrations 
against Streptococcus spp. isolates; A) B012 V1S1Q (S. anginosus), B) C063 V1S1B 
(S. constellatus), C) B003 V1S1T (S. constellatus), D) B024 V1S1D (S. mitis), E) NCTC 
10713 (S. anginosus).  
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